OncoMatch

OncoMatch/Clinical Trials/NCT05320198

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Is NCT05320198 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies DISC-0974 for myelofibrosis; anemia.

Phase 1/2RecruitingDisc Medicine, IncNCT05320198Data as of Jun 2026Location: United States · Australia

Treatment: DISC-0974This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

DISC-0974

Cancer type

Myeloproliferative Neoplasm

Myelodysplastic Syndrome

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: iron chelation therapy

Iron chelation therapy in the 28 days prior to Screening

Cannot have received: hypomethylating agent or other acute myeloid leukemia (AML)-like combination chemotherapy

Prior treatment with hypomethylating agent or other acute myeloid leukemia (AML)-like combination chemotherapy

Lab requirements

Blood counts

Platelet count ≥25,000/μL and <1,000,000/μL; neutrophils ≥1,000/μL; total WBC count <50,000/μL at Screening

Kidney function

eGFR ≥30 mL/min/1.73 m2 by the CKD-EPI formula

Liver function

AST and ALT <3x ULN at Screening; Direct bilirubin <2x ULN at Screening. Higher levels are acceptable if attributed to ineffective erythropoiesis or Gilbert's syndrome (with approval from Sponsor).

Platelet count ≥25,000/μL and <1,000,000/μL; neutrophils ≥1,000/μL; total WBC count <50,000/μL at Screening. eGFR ≥30 mL/min/1.73 m2 by the CKD-EPI formula. AST and ALT <3x ULN at Screening. Direct bilirubin <2x ULN at Screening.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • City of Hope - Duarte · Duarte, California
  • City of Hope - Lennar · Irvine, California
  • University of Colorado Anschutz Medical Campus · Aurora, Colorado
  • Mayo Clinic Jacksonville · Jacksonville, Florida
  • Sylvester Cancer Center - U Miami · Miami, Florida

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT05320198 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior iron chelation therapy, hypomethylating agent or other acute myeloid leukemia (AML)-like combination chemotherapy disqualifies patients from enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify